VEGFR2 small molecule inhibitors are successfully used on a grand scale for the treatment of several forms of cancer including hepatocellular carcinoma (HCC) [16], metastatic renal carcinoma [17], thyroid cancer [18], gastrointestinal stromal tumor, melanoma, and colorectal cancer [19,20,21]. This evidence concerns the gene KDR and hepatocellular carcinoma.